|Dr. André Choulika||Co-Founder, Chairman & CEO||N/A||N/A||1965|
|Dr. David J. D. Sourdive||Co-Founder, Deputy CEO, Exec. VP of Strategic Initiatives & Director||N/A||N/A||1967|
|Mr. Eric Dutang||Chief Financial Officer||N/A||N/A||1974|
|Mr. Jean Charles Epinat||Chief Technological Officer||N/A||N/A||N/A|
|Mr. Stephan Reynier||Chief Regulatory & Compliance Officer||N/A||N/A||1969|
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.
Cellectis S.A.’s ISS Governance QualityScore as of October 4, 2019 is 10. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 6; Compensation: 10.